Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M

RIGEL PHARMACEUTICALS INC

2025-Q2 EPS reported $3.91 vs consensus $2.63 ▲ beat (+48.6%)

Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.
Raised FY2025 guidance: total revenue $270-280M (prev $200-210M); net product sales $210-220M (prev $185-192M).
Cash and investments increased to $108.4M from $77.3M at Dec 31, 2024.
TAVALISSE sales $40.1M (+52% YoY), GAVRETO $11.8M, REZLIDHIA $7.0M (+36%).
Completed enrollment in dose escalation part of Phase 1b study for R289 in R/R lower-risk MDS; dose expansion later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.